KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Opko Health (OPK) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Opko Health (OPK) over the last 16 years, with Q3 2025 value amounting to $101.8 million.

  • Opko Health's Cost of Revenue fell 2376.5% to $101.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $415.5 million, marking a year-over-year decrease of 3161.31%. This contributed to the annual value of $494.6 million for FY2024, which is 930.31% down from last year.
  • As of Q3 2025, Opko Health's Cost of Revenue stood at $101.8 million, which was down 2376.5% from $107.4 million recorded in Q2 2025.
  • Opko Health's 5-year Cost of Revenue high stood at $339.4 million for Q1 2021, and its period low was $99.0 million during Q4 2024.
  • Its 5-year average for Cost of Revenue is $167.1 million, with a median of $131.6 million in 2024.
  • Per our database at Business Quant, Opko Health's Cost of Revenue skyrocketed by 17621.23% in 2021 and then plummeted by 5329.15% in 2024.
  • Over the past 5 years, Opko Health's Cost of Revenue (Quarter) stood at $271.7 million in 2021, then dropped by 28.33% to $194.8 million in 2022, then increased by 8.81% to $211.9 million in 2023, then crashed by 53.29% to $99.0 million in 2024, then increased by 2.83% to $101.8 million in 2025.
  • Its Cost of Revenue was $101.8 million in Q3 2025, compared to $107.4 million in Q2 2025 and $107.3 million in Q1 2025.